作者
Giovanni Addolorato, Fabio Caputo, Esmeralda Capristo, Luigi Janiri, Mauro Bernardi, Roberta Agabio, Giancarlo Colombo, Gian Luigi Gessa, Giovanni Gasbarrini
发表日期
2002/2/15
期刊
The American journal of medicine
卷号
112
期号
3
页码范围
226-229
出版商
Elsevier
简介
Alcohol withdrawal syndrome is a distressing and at times life-threatening condition in alcohol-dependent patients (1). Usually, symptoms develop within 6–24 hours after the last drink (2). Early symptoms include raised blood pressure and pulse rate, tremor, hyperreflexia, and anxiety with increased irritability. Clinical management is aimed at symptom relief, prevention of seizures and delirium, and a smooth transition to a treatment program to maintain long-term abstinence from alcohol (3). Benzodiazepines are presently the drug of choice (4).
We recently found that baclofen, a-aminobutyric acid (GABA) B receptor agonist used to control spasticity (5), reduced voluntary alcohol intake in alcohol-preferring rats (6), as well as alcohol craving and intake, up to complete alcohol abstinence, in alcohol-dependent patients (7). Furthermore, baclofen suppressed the intensity of alcohol withdrawal syndrome in rats who were …
引用总数
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320245102313875814697108743925311
学术搜索中的文章
G Addolorato, F Caputo, E Capristo, L Janiri… - The American journal of medicine, 2002